Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge Olema Pharmaceuticals (
NASDAQ:OLMA ) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by a "rising tide" effect in the breast cancer treatment market—top insiders have begun offloading significant portions of their
Olema Insider Sells $8 Million in Shares After 300% Stock Surge Focused on therapies for women's cancers, this clinical-stage biotech reported a significant insider sale amid a year of sharp stock gains.
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter
Keep an eye on the top gainers and losers in Thursday's session. Curious about what's happening in today's session? Check out the latest stock movements and price changes.
In today's session, these stocks are experiencing unusual volume. Let's explore the current happenings on the US markets on Wednesday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Biotech Stock Gets Booted in Latest Fund Update Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock Bain Capital completely exited its position in Disc Medicine stock during the third quarter
Which stocks are moving on Tuesday? Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Why Bain Capital Is Selling Shares of This Biotech Stock Now Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.
Which stocks are most active on Tuesday? Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume!
Top movers in Tuesday's session Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock "Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock.
Let's uncover which stocks are experiencing notable gaps during today's session. Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.
Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile.
Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% The companies are both working on oral selective estrogen receptor degraders, which break down the estrogen cancer cells need to grow.
